UNSW receives over $3 million in funding to support cancer and rare disease research – India Education | Latest Education News | World Education News

UNSW Sydney researchers have been awarded over $3 million from the 2021 Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) grant program funded by the Medical Research Futures Fund (MRFF).

The two UNSW grants were among 27 projects funded by RCRDUN, which aims to increase clinical trial activity in Australia for cancers and rare diseases by supporting new, high-quality research.

Cancers and rare diseases are specific, life-threatening or chronically debilitating health conditions that affect less than 1 in 2000 people.

UNSW Medicine and Health Associate Professor David Ziegler and senior staff specialist at Kids Cancer Center at Sydney Children’s Hospital will lead a platform trial of precision-guided combination therapies for high-risk childhood cancer.

Professor James McAuley, at UNSW Medicine & Health and Principal Investigator at Neuroscience Research Australia (NeuRA), will lead research to improve the lives of people with phantom limb pain.

The Dean of UNSW Medicine & Health, Scientia Professor Vlado Perkovic congratulated the researchers for receiving the grants.

“These successes demonstrate the innovative nature of projects aimed at improving the lives of patients with rare diseases,” said Professor Perkovic.

“This is an incredible achievement for our researchers, and I commend them for the great work they are doing to ensure better health outcomes for communities.

Support for high-risk childhood cancers

Teacher. Ziegler’s project received $1,515,180 to test combinations of precision-guided therapies for high-risk childhood cancer, based on each child’s individual tumor profile.

Located at Sydney Children’s Hospital, the project will support targeted treatments based on precision medicine for children with the most aggressive cancers.

“This funding will allow us to open up research in all children’s centers across the country, not just in New South Wales, which is incredibly exciting,” said A/Prof. Ziegler.

“This program is open to all children with cancer, to those whose standard treatment has failed.

“This will give them access to new cutting-edge targeted therapies.”

Phantom Limb Pain Relief

About 80% of single limb amputees experience pain in the ‘missing’ limb, known as ‘phantom limb pain’.

Awarded $1,531,130, the TITAN trial project led by Professor McAuley will see world-renowned Australian researchers from UNSW, the University of South Australia and Monash University collaborate to test the treatment most promising non-drug therapy for phantom limb pain.

“Phantom pain and sensations can be very intense and disturbing, and there is no intervention for phantom limb pain that is backed by high-quality research,” Professor McAuley said.

“Many people with phantom limb pain resort to strong painkillers that often have side effects.

“Medications can help with pain but do not offer a lasting solution. Non-drug treatments are a promising alternative that aims to cure phantom limb pain.

TITAN is the largest clinical trial conducted for people with phantom limb pain and will enroll 180 people with the condition across Australia.

Comments are closed.